// App-Quantinova.ai

: Subcutaneous Epcoritamab in Novel Combinations with Antineoplastic Agents Among Patients with B-Cell Non-Hodgkin Lymphoma in a Phase 1b/2, Multicenter, Open-Label Study: Assessing Safety, Tolerability, and Preliminary Efficacy (EPCORE NHL-5)

Researchers

Presenter

  • Laurie H. Sehn

Principal Investigators

  • Johannes Duell

  • Irit Avivi

  • Joshua Brody

  • Dok Hyun Yoon

  • Brian Elliot

  • Satya R. Siddani

  • Yang Bai

  • Apurvasena Parikh

  • Mostafa M. Seliem

  • Minh Dinh

  • Alan P. Skarbnik

Medical Centers

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, Canada

  • Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

  • Medizinische Klinik und Poliklinik II, Universitätsklinik Würzburg, Würzburg, Germany

  • Lymphoma and CLL Program, Novant Health Cancer Institute, Charlotte, NC

  • Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of (South)

Locations

  • United States

  • Israel

  • Germany

  • Canada

  • Republic of South Korea

Companies

  • AbbVie Inc.

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Oncology (ONC)

Disease

  • B-Cell Non-Hodgkin Lymphoma

  • Follicular lymphoma

  • Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Lymphomas

  • Diffuse large B-cell lymphoma

Biomarkers

  • B-lymphocyte antigen CD20

  • Cluster of Differentiation 2AP

  • Apparent diffusion coefficient

Drug/Treatment

  • Sandolase

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

  • Pharmacokinetics

  • Open Label

  • Multicenteric

  • Tolerability

  • Immunogenicity

  • Dose Escalation

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved